Agennix concludes patient recruitment in Talactoferrin Phase III FORTIS-M trial

The FORTIS-M Phase III trial is investigating Talactoferrin plus best supportive care compared to placebo plus best supportive care in patients with non-small cell lung cancer (NSCLC) whose disease has progressed following two or more prior treatment regimens.

Agennix chief medical officer Rajesh Malik said they are excited to have accomplished this important milestone in the development of Talactoferrin by completing accrual in the FORTIS-M trial within the expected timeline.

"There is a major need for effective and well-tolerated treatments for non-small cell lung cancer patients whose disease has already progressed after multiple therapies," Malik said.